Dr Post has experience in oncolytic viruses and virotherapy having been a past director of and consultant to Biovex Ltd, recently acquired by Amgen Inc in 2011. He was also Senior Vice President of R&D at Onyx Pharmaceuticals which was one of the first companies involved in the development of targeted oncolytic viruses. Prior to this, his experience covers almost 20 years with international pharmaceutical companies. He has a commercial background which includes founding US-based LEAD Therapeutics Inc. in 2007 which was subsequently acquired by BioMarin Pharmaceuticals Inc in 2010. He currently serves as Chief Scientific Officer of BioMarin Pharmaceutical, is a director of three USA-based biotechnology companies and has been a member of a number of Scientific Advisory Boards. He is also an advisor to well-known Australian based venture capital firm.